Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy in advanced cervical cancer
ChiCTR2100045387Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Cervical Cancer (CC), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100045387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045387.